Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Major

epoetin alfa belzutifan

Applies to: Retacrit (epoetin alfa), belzutifan

GENERALLY AVOID: Coadministration of belzutifan with erythropoiesis-stimulating agents (ESAs) may increase the risk of adverse events. Randomized controlled trials have demonstrated that ESAs may increase the risks of death and serious cardiovascular reactions and decrease progression-free survival and/or overall survival in cancer patients treated with myelosuppressive chemotherapy and ESAs. Safety and effectiveness of ESAs have not been established in belzutifan-treated patients who develop anemia.

MANAGEMENT: Use of ESAs for the treatment of anemia in patients receiving belzutifan is not recommended.

References (1)
  1. (2021) "Product Information. Welireg (belzutifan)." Merck & Co., Inc

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer